{"transactions":[{"id":4625490,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-23T20:36:12.000Z","date":"2026-09-21","kind":"gift","planned":false,"acquired":false,"shares":36652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 21, 2026, the reporting person transferred 36,652 shares of the Issuer's Common Stock to The Hallal Family Irrevocable Trust-2021 (the \"Hallal 2021 Trust\") for no consideration. The reporting person and his spouse serve as trustees of the Hallal 2021 Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 161,878 shares of common stock, 315,504 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions."}],"balance_after":1602382,"source":{"system":"sec-edgar","filing":"0001104659-26-110006","document":"tm2626025-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926110006/tm2626025-1_4seq1.xml","form_type":"4"}},{"id":749662,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:28:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257494/ownership.xml","form_type":"4"}},{"id":804507,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T22:08:37.000Z","date":"2026-04-16","kind":"sale","planned":false,"acquired":false,"shares":30615,"price":49.5745,"value":1517723.3175,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units (\"RSUs\") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 198,530 shares of common stock, 315,504 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions."}],"balance_after":1639034,"source":{"system":"sec-edgar","filing":"0001104659-26-045581","document":"tm2612274-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926045581/tm2612274-1_4seq1.xml","form_type":"4"}},{"id":909978,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-11T23:06:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":128004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 166,645 shares of common stock, 378,004 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions."}],"balance_after":1669649,"source":{"system":"sec-edgar","filing":"0001104659-26-013580","document":"tm266077-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926013580/tm266077-2_4seq1.xml","form_type":"4"}},{"id":938515,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T00:54:11.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":57450,"price":42.7,"value":2453115.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance-and time-based vesting conditions (\"PSUs\"). The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued) The shares vested pursuant to awards that were granted on April 27, 2025. 125,000 shares subject to this PSU vested on January 12, 2026, with an additional 125,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four year, provided the Reporting Person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"166,645 shares of common stock, 250,000 restricted stock units and 1,125,000 PSUs."}],"balance_after":1541645,"source":{"system":"sec-edgar","filing":"0001104659-26-004221","document":"tm263352-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926004221/tm263352-1_4seq1.xml","form_type":"4"}},{"id":1020837,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-09T21:30:57.000Z","date":"2025-10-08","kind":"gift","planned":false,"acquired":false,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 8, 2025, the Reporting Person transferred 205,000 shares of the Issuer's Common Stock to the Hallal Family Irrevocable Trust - 2012 dated November 19, 2012 (the \"Hallal Trust\") for no consideration. The Reporting Person's spouse serves as a trustee of the Hallal Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 99,095 shares of Common Stock and 1,500,000 restricted stock units."}],"balance_after":1599095,"source":{"system":"sec-edgar","filing":"0001457477-25-000004","document":"form4-10092025_091053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000145747725000004/form4-10092025_091053.xml","form_type":"4"}},{"id":1052954,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:04.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146160,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":146160},"source":{"system":"sec-edgar","filing":"0001193125-25-192818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192818/ownership.xml","form_type":"4"}},{"id":1052953,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:04.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25140,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the \"Cash Amount\") (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.95,"underlying":"Common Stock","underlying_shares":25140},"source":{"system":"sec-edgar","filing":"0001193125-25-192818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192818/ownership.xml","form_type":"4"}},{"id":1119815,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":false,"shares":38228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":0,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":38228},"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119814,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":false,"shares":38227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":38228,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":38227},"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119813,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":false,"shares":38227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":76455,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":38227},"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119812,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-06","kind":"sale","planned":true,"acquired":false,"shares":38228,"price":10.24,"value":391454.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119811,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":true,"shares":38228,"price":4.3,"value":164380.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":38228,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119810,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-05","kind":"sale","planned":true,"acquired":false,"shares":38227,"price":10.15,"value":388004.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119809,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":true,"shares":38227,"price":4.3,"value":164376.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":38227,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119808,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-04","kind":"sale","planned":true,"acquired":false,"shares":38227,"price":10.07,"value":384945.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1119807,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T21:03:02.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":true,"shares":38227,"price":4.3,"value":164376.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025"}],"balance_after":38227,"source":{"system":"sec-edgar","filing":"0000950170-25-083410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025083410/ownership.xml","form_type":"4"}},{"id":1157423,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-06T21:00:23.000Z","date":"2025-05-02","kind":"grant","planned":false,"acquired":true,"shares":275167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service\nrelationship with the Issuer on each such vesting date."}],"balance_after":275167,"derivative":{"exercise_price":32.91,"expiration_date":"2035-05-02","underlying":"Common Stock","underlying_shares":275167},"source":{"system":"sec-edgar","filing":"0001104659-25-045112","document":"tm2513936-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925045112/tm2513936-1_4seq1.xml","form_type":"4"}},{"id":1163933,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-29T22:07:02.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance based RSUs subject to performance- and time-based vesting conditions (the \"PSUs\"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration."}],"balance_after":1804095,"source":{"system":"sec-edgar","filing":"0001104659-25-041457","document":"tm2513505-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925041457/tm2513505-5_4seq1.xml","form_type":"4"}},{"id":1163932,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-29T22:07:02.000Z","date":"2025-04-27","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") subject to time-based vesting conditions. Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date."}],"balance_after":554095,"source":{"system":"sec-edgar","filing":"0001104659-25-041457","document":"tm2513505-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925041457/tm2513505-5_4seq1.xml","form_type":"4"}},{"id":1173311,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:41:02.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053318/ownership.xml","form_type":"4"}},{"id":1465838,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T21:12:51.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."}],"balance_after":18000,"derivative":{"exercise_price":8.36,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001415889-24-018627","document":"form4-07012024_090748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588924018627/form4-07012024_090748.xml","form_type":"4"}},{"id":1465837,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-01T21:12:51.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest  on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 290,595 shares of common stock and 13,500 RSUs."}],"balance_after":304095,"source":{"system":"sec-edgar","filing":"0001415889-24-018627","document":"form4-07012024_090748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588924018627/form4-07012024_090748.xml","form_type":"4"}},{"id":1479075,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-14T20:19:09.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":58178,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":355128,"source":{"system":"sec-edgar","filing":"0001415889-24-016896","document":"form4-06142024_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000141588924016896/form4-06142024_080606.xml","form_type":"4"}},{"id":1480820,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T20:00:08.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":24200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24200,"derivative":{"exercise_price":16.32,"exercise_date":"2025-06-11","expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":24200},"source":{"system":"sec-edgar","filing":"0000950170-24-073254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017024073254/ownership.xml","form_type":"4"}},{"id":1486927,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:13.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":2143662,"source":{"system":"sec-edgar","filing":"0000950170-24-070600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070600/ownership.xml","form_type":"4"}},{"id":1846580,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-22T22:47:11.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."}],"balance_after":36000,"derivative":{"exercise_price":9.11,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001415889-23-010194","document":"form4-06222023_100606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588923010194/form4-06222023_100606.xml","form_type":"4"}},{"id":1852395,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-17T01:16:47.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":34735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34735,"derivative":{"exercise_price":4.33,"expiration_date":"2033-06-14","underlying":"Class A Common Stock","underlying_shares":34735},"source":{"system":"sec-edgar","filing":"0001209191-23-038189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000120919123038189/doc4.xml","form_type":"4"}},{"id":1852394,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-17T01:16:47.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":23443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":296950,"source":{"system":"sec-edgar","filing":"0001209191-23-038189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000120919123038189/doc4.xml","form_type":"4"}},{"id":1854539,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T19:54:10.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":22383,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22383,"derivative":{"exercise_price":14.77,"exercise_date":"2024-06-13","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":22383},"source":{"system":"sec-edgar","filing":"0001209191-23-037590","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919123037590/doc4.xml","form_type":"4"}},{"id":1895163,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T21:00:41.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":2108662,"source":{"system":"sec-edgar","filing":"0001209191-23-029102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123029102/doc4.xml","form_type":"4"}},{"id":2133583,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-22T01:30:12.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":600000,"price":8.45,"value":5070000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":138153,"source":{"system":"sec-edgar","filing":"0000899243-22-033994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322033994/doc4.xml","form_type":"4"}},{"id":2148718,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T20:05:12.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":400000,"price":7.3523,"value":2940920.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.35 to $8.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":720965,"source":{"system":"sec-edgar","filing":"0000899243-22-032297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322032297/doc4.xml","form_type":"4"}},{"id":2199114,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:38:08.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":3253796,"price":4.61,"value":14999999.56,"ownership":{"direct":false,"nature":"By ElevateBio LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, ElevateBio LLC (\"ElevateBio\") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio. The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":16674766,"source":{"system":"sec-edgar","filing":"0000899243-22-027173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027173/doc4.xml","form_type":"4"}},{"id":2203978,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-21T23:13:00.000Z","date":"2022-07-21","kind":"sale","acquired":false,"shares":4227,"price":5.3295,"value":22527.7965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.26 to $5.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2073662,"source":{"system":"sec-edgar","filing":"0000899243-22-026519","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322026519/doc4.xml","form_type":"4"}},{"id":2225487,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-21T21:01:49.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the first anniversary following the date of grant subject to continued service to the Issuer through such date."}],"balance_after":14000,"derivative":{"exercise_price":4.86,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-22-073027","document":"tm2218901-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465922073027/tm2218901-3_4seq1.xml","form_type":"4"}},{"id":2228006,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T22:36:09.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":29640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":29640,"derivative":{"exercise_price":7.33,"expiration_date":"2031-06-15","underlying":"Class A Common Stock","underlying_shares":29640},"source":{"system":"sec-edgar","filing":"0001209191-22-038097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000120919122038097/doc4.xml","form_type":"4"}},{"id":2228005,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-17T22:36:09.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":9945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":273507,"source":{"system":"sec-edgar","filing":"0001209191-22-038097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000120919122038097/doc4.xml","form_type":"4"}},{"id":2236231,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":17538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":17538,"derivative":{"exercise_price":18.78,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":17538},"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236230,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-09","kind":"exercise","acquired":false,"shares":1171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":146160,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":1171},"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236229,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":false,"shares":10577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":147331,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":10577},"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236228,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":false,"shares":11899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":25140,"derivative":{"exercise_price":2.95,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":11899},"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236227,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":false,"shares":5968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":157908,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":5968},"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236226,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-09","kind":"sale","acquired":false,"shares":1171,"price":19.51,"value":22846.21,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.37 to $19.62, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236225,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-09","kind":"exercise","acquired":true,"shares":1171,"price":4.23,"value":4953.33,"ownership":{"direct":true},"balance_after":1171,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236224,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":10577,"price":19.86,"value":210059.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.12, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236223,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":true,"shares":10577,"price":4.23,"value":44740.71,"ownership":{"direct":true},"balance_after":10577,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236222,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":11899,"price":20.39,"value":242620.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236221,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":true,"shares":11899,"price":2.95,"value":35102.05,"ownership":{"direct":true},"balance_after":11899,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236220,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":5968,"price":20.39,"value":121687.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2236219,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T19:51:29.000Z","date":"2022-06-08","kind":"exercise","acquired":true,"shares":5968,"price":4.23,"value":25244.64,"ownership":{"direct":true},"balance_after":5968,"source":{"system":"sec-edgar","filing":"0001209191-22-036137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036137/doc4.xml","form_type":"4"}},{"id":2242480,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T20:05:18.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":65725,"price":3.6684,"value":241105.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2077889,"source":{"system":"sec-edgar","filing":"0000899243-22-021183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322021183/doc4.xml","form_type":"4"}},{"id":2253586,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:34:09.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting subject to continued service to the Issuer through such date."}],"balance_after":28000,"derivative":{"exercise_price":4.75,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-22-065953","document":"tm2216969-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465922065953/tm2216969-5_4seq1.xml","form_type":"4"}},{"id":2263866,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:24:03.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":27500,"derivative":{"exercise_price":4.6,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0000899243-22-018821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322018821/doc4.xml","form_type":"4"}},{"id":2291873,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-22T12:31:45.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":4227,"price":5.87,"value":24812.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units."}],"balance_after":2143614,"source":{"system":"sec-edgar","filing":"0000899243-22-015395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322015395/doc4.xml","form_type":"4"}},{"id":2337729,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-12T00:14:59.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":25244,"price":7.3708,"value":186068.4752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request"}],"balance_after":2147841,"source":{"system":"sec-edgar","filing":"0000899243-22-010762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322010762/doc4.xml","form_type":"4"}},{"id":2337728,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-12T00:14:59.000Z","date":"2022-03-10","kind":"sale","acquired":false,"shares":40481,"price":7.5537,"value":305781.3297,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.27 to $7.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2173085,"source":{"system":"sec-edgar","filing":"0000899243-22-010762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322010762/doc4.xml","form_type":"4"}},{"id":2426788,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T21:15:11.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":17100,"price":8.0052,"value":136888.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the reporting person to cover tax withholding obligations upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.51 to $8.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2213566,"source":{"system":"sec-edgar","filing":"0000899243-22-003144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322003144/doc4.xml","form_type":"4"}},{"id":2461207,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T19:59:57.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vested on December 5, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":37039,"derivative":{"exercise_price":2.95,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-070993","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919121070993/doc4.xml","form_type":"4"}},{"id":2461206,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T19:59:57.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares subject to the stock option vested on July 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":114682,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-070993","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919121070993/doc4.xml","form_type":"4"}},{"id":2461205,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T19:59:57.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":50000,"price":43.57,"value":2178500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.19, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-070993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919121070993/doc4.xml","form_type":"4"}},{"id":2461204,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T19:59:57.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":30000,"price":2.95,"value":88500.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-21-070993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919121070993/doc4.xml","form_type":"4"}},{"id":2461203,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T19:59:57.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":20000,"price":4.3,"value":86000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-21-070993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919121070993/doc4.xml","form_type":"4"}},{"id":2658938,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T22:28:20.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 17, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":33.74,"expiration_date":"2031-06-17","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-042503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000120919121042503/doc4.xml","form_type":"4"}},{"id":2661411,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:13:38.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":16608,"derivative":{"exercise_price":26.03,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-21-025122","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924321025122/doc4.xml","form_type":"4"}},{"id":2689093,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-01T20:17:03.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting."}],"balance_after":7800,"derivative":{"exercise_price":26.78,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001179110-21-006147","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000117911021006147/edgar.xml","form_type":"4"}},{"id":2693589,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-27T20:54:59.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":21.51,"expiration_date":"2031-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-21-020869","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321020869/doc4.xml","form_type":"4"}},{"id":2897871,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-25T22:04:31.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":273000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest and become exercisable on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":273000,"derivative":{"exercise_price":45.04,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":273000},"source":{"system":"sec-edgar","filing":"0000899243-21-003181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321003181/doc4.xml","form_type":"4"}},{"id":2897870,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-25T22:04:31.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":147000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":2230666,"source":{"system":"sec-edgar","filing":"0000899243-21-003181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321003181/doc4.xml","form_type":"4"}},{"id":2948751,"issuer":{"id":6717,"kind":"organization","name":"Seer, Inc.","symbol":"SEER"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-12T02:11:04.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":18691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on January 3, 2021."}],"balance_after":18691,"derivative":{"exercise_price":19,"expiration_date":"2020-12-03","underlying":"Class A Common Stock","underlying_shares":18691},"source":{"system":"sec-edgar","filing":"0001628280-20-017429","document":"wf-form4_160773905141176.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726445/000162828020017429/wf-form4_160773905141176.xml","form_type":"4"}},{"id":3002277,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-21T16:56:46.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the vesting schedule, as follows: this stock option shall vest on the earlier of (i) the first anniversary of the grant date or (ii) the Company's next annual meeting of stockholders following the grant date, subject to continued service through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-20-028904","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924320028904/doc4a.xml","form_type":"4/A","original_submission_date":"2020-07-24"}},{"id":3067704,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A-4 Convertible Preferred Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":1100000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":738153},"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3067703,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A-4 Convertible Preferred Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":233333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":156577},"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3067702,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":20000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio LLC (\"ElevateBio\"). The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13420970},"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3067701,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":738153,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":738153,"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3067700,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":156577,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1120965,"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3067699,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:56:10.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":13420970,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio LLC (\"ElevateBio\"). The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":13420970,"source":{"system":"sec-edgar","filing":"0000899243-20-021587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021587/doc4.xml","form_type":"4"}},{"id":3072601,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:46:35.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":1101000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":1101000,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":1101000},"source":{"system":"sec-edgar","filing":"0000899243-20-020935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020935/doc4.xml","form_type":"4"}},{"id":3076296,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-24T19:23:16.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over 3 years, with 1/3 vesting on July 23, 2021 and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service to the Issuer."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-20-020442","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924320020442/doc4.xml","form_type":"4"}},{"id":3105652,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:32:32.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting."}],"balance_after":7000,"derivative":{"exercise_price":17.65,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001179110-20-007547","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000117911020007547/edgar.xml","form_type":"4"}},{"id":3105651,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:32:32.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting."}],"balance_after":13000,"derivative":{"exercise_price":17.65,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001179110-20-007547","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000117911020007547/edgar.xml","form_type":"4"}},{"id":3409115,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T20:39:01.000Z","date":"2019-09-18","kind":"gift","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Company's common stock transferred as a gift for no consideration to a family member subject to additional transfer restrictions."}],"balance_after":290595,"source":{"system":"sec-edgar","filing":"0001179110-19-010518","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000117911019010518/edgar.xml","form_type":"4"}},{"id":3513606,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T01:42:30.000Z","date":"2019-05-21","kind":"grant","acquired":true,"shares":10158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting."}],"balance_after":10158,"derivative":{"exercise_price":21.21,"expiration_date":"2029-05-21","underlying":"Common Stock","underlying_shares":10158},"source":{"system":"sec-edgar","filing":"0001104659-19-031595","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465919031595/a4.xml","form_type":"4"}},{"id":3883225,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-26T21:30:42.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":20316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly over three (3) years, with the first monthly amount vesting on June 29, 2018."}],"balance_after":20316,"derivative":{"exercise_price":21.62,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":20316},"source":{"system":"sec-edgar","filing":"0001104659-18-042340","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465918042340/a4.xml","form_type":"4"}}]}